Literature DB >> 25944562

Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma.

Peter Ugocsai1, Daniel Wolff1, Karin Menhart2, Dirk Hellwig2, Ernst Holler1, Wolfgang Herr1, Albrecht Reichle3.   

Abstract

Entities:  

Keywords:  biomodulatory therapy; everolimus; metronomic therapy; pioglitazone; refractory Hodgkin lymphoma

Mesh：

Substances：

Year:  2015        PMID： 25944562     DOI： 10.1111/bjh.13480

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Drug Repurposing by Tumor Tissue Editing.

Authors:  Florian Lüke; Dennis Christoph Harrer; Pan Pantziarka; Tobias Pukrop; Lina Ghibelli; Christopher Gerner; Albrecht Reichle; Daniel Heudobler
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

2.  Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia.

Authors:  Rupert L Mayer; Josef D Schwarzmeier; Marlene C Gerner; Andrea Bileck; Johanna C Mader; Samuel M Meier-Menches; Samuel M Gerner; Klaus G Schmetterer; Tobias Pukrop; Albrecht Reichle; Astrid Slany; Christopher Gerner
Journal:  Mol Cell Proteomics       Date:  2017-12-01       Impact factor: 5.911

Review 3.  Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.

Authors:  Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Tobias Pukrop; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle
Journal:  Int J Mol Sci       Date:  2018-11-09       Impact factor: 5.923

Review 4.  Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.

Authors:  Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Sebastian Klobuch; Simone Thomas; Tobias Pukrop; Christina Hackl; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810

5.  Proteome Analysis Reveals Distinct Mitochondrial Functions Linked to Interferon Response Patterns in Activated CD4+ and CD8+ T Cells.

Authors:  Marlene C Gerner; Laura Niederstaetter; Liesa Ziegler; Andrea Bileck; Astrid Slany; Lukas Janker; Ralf L J Schmidt; Christopher Gerner; Giorgia Del Favero; Klaus G Schmetterer
Journal:  Front Pharmacol       Date:  2019-07-10       Impact factor: 5.810

6.  Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin's Disease.

Authors:  Florian Lüke; Dennis C Harrer; Karin Menhart; Daniel Wolff; Ernst Holler; Dirk Hellwig; Wolfgang Herr; Matthias Grube; Martin Vogelhuber; Albrecht Reichle; Daniel Heudobler
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

7.  Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.

Authors:  Christina Hart; Martin Vogelhuber; Daniel Wolff; Sebastian Klobuch; Lina Ghibelli; Jürgen Foell; Selim Corbacioglu; Klaus Rehe; Guy Haegeman; Simone Thomas; Wolfgang Herr; Albrecht Reichle
Journal:  Cancer Microenviron       Date:  2015-08-11

8.  Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction.

Authors:  Emanuele Bruni; Albrecht Reichle; Manuel Scimeca; Elena Bonanno; Lina Ghibelli
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.